Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 4Plasma cell 2Myeloid 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Primary Myelofibrosis 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia 1Glioblastoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 8Nivolumab 6Gemcitabine 5spartalizumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3Azacitidine 3toripalimab 2fludarabine 2epacadostat 2atezolizumab 2Therapeutics 2Sirolimus 2Paclitaxel 2Interleukin-2 2Epoetin Alfa 2Cisplatin 2Bevacizumab 2vocimagene amiretrorepvec 1vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1sargramostim 1sapanisertib 1ruxolitinib 1rucaparib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × ruxolitinib × Thoracic × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡